• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.

作者信息

Chiang Chi-Lu, Yeh Yi-Chen, Chou Teh-Ying, Chiu Chao-Hua

机构信息

Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

出版信息

J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.

DOI:10.1016/j.jfma.2019.12.017
PMID:32173232
Abstract
摘要

相似文献

1
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.一名患有罕见表皮生长因子受体（EGFR）突变的肺腺癌患者在对奥希替尼产生获得性耐药后发生鳞状细胞癌转化。
J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.
2
Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.一名EGFR突变型肺腺癌患者在对奥希替尼产生获得性耐药后，肿瘤先转变为鳞状细胞癌，后又转变为肉瘤样癌：病例报告
Clin Lung Cancer. 2021 Jul;22(4):e536-e541. doi: 10.1016/j.cllc.2020.06.026. Epub 2020 Jul 5.
3
Osimertinib for Secondary T790M-Mutation-Positive Squamous Cell Carcinoma Transformation After Afatinib Failure.奥希替尼用于阿法替尼治疗失败后的继发性T790M突变阳性鳞状细胞癌转化
J Thorac Oncol. 2018 Dec;13(12):e252-e254. doi: 10.1016/j.jtho.2018.07.100.
4
Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.克服第三代 EGFR-TKI 奥希替尼治疗 T790M 突变小细胞肺癌。
Thorac Cancer. 2019 Feb;10(2):359-364. doi: 10.1111/1759-7714.12927. Epub 2018 Dec 6.
5
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.利用下一代测序技术探索非小细胞肺癌患者二线奥希替尼的耐药机制及其预后意义。
Eur J Cancer. 2021 May;148:202-210. doi: 10.1016/j.ejca.2021.01.052. Epub 2021 Mar 18.
6
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.Sunvozertinib克服携带EGFR外显子18 DelE709_T710insD突变的肺腺癌对阿法替尼和奥希替尼的耐药性。
J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.
7
Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.通过循环肿瘤DNA分析对接受奥希替尼治疗的表皮生长因子受体（EGFR）突变型肺腺癌患者的多种耐药机制进行早期检测
Clin Lung Cancer. 2020 Sep;21(5):e488-e492. doi: 10.1016/j.cllc.2020.03.009. Epub 2020 Apr 9.
8
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.携罕见 EGFR L747P 突变的非小细胞肺癌对吉非替尼和奥希替尼（AZD9291）均表现出内在耐药性：一例报告。
Thorac Cancer. 2018 Jun;9(6):745-749. doi: 10.1111/1759-7714.12637. Epub 2018 Apr 19.
9
Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.肺腺癌中携带 EGFR T751I759delinsS 突变的阿法替尼和奥希替尼治疗：一例报告。
Thorac Cancer. 2021 Dec;12(24):3429-3432. doi: 10.1111/1759-7714.14215. Epub 2021 Nov 2.
10
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.奥希替尼治疗后低剂量厄洛替尼导致 EGFR 突变型肺腺癌转化为 T790M 突变阳性鳞状细胞癌：病例报告及文献复习。
Medicine (Baltimore). 2022 Aug 12;101(32):e29682. doi: 10.1097/MD.0000000000029682.

引用本文的文献

1
Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation.揭示肺腺鳞癌转化中的免疫机制和治疗靶点。
Front Immunol. 2025 Jun 3;16:1542526. doi: 10.3389/fimmu.2025.1542526. eCollection 2025.
2
Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review.腺癌向鳞状细胞癌转化作为表皮生长因子受体酪氨酸激酶抑制剂耐药的一个来源：一例病例报告及文献综述
Front Oncol. 2022 Sep 8;12:942084. doi: 10.3389/fonc.2022.942084. eCollection 2022.